Literature DB >> 23997055

Significance of connective tissue diseases features in pulmonary fibrosis.

Vincent Cottin1.   

Abstract

Interstitial lung disease (ILD) can occur in any of the connective tissue diseases (CTD) with varying frequency and severity, and an overall long-term prognosis that is less severe than that of idiopathic pulmonary fibrosis (IPF). Because ILD may be the presenting manifestation of CTD and/or the dominant manifestation of CTD, clinical extra-thoracic manifestations should be systematically considered in the diagnostic approach of ILD. When present, autoantibodies strongly contribute to the recognition and classification of the CTD. Patients with clinical extrathoracic manifestations of CTD and/or autoantibodies (especially with a high titer and/or the antibody is considered "highly specific" of an autoimmune condition), but who do not fit with established international CTD criteria may be called undifferentiated CTD or "lung-dominant CTD". Although it remains to be determined which combination of symptoms and serologic tests best identify the subset of patients with clinically relevant CTD features, available evidence suggests that such patients may have distinct clinical and imaging presentation and may portend a distinct clinical course. However, autoantibodies alone when present in IPF patients do not seem to impact prognosis or management. Referral to a rheumatologist and multidisciplinary discussion may contribute to management of patients with undifferentiated CTD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23997055     DOI: 10.1183/09059180.00003013

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  19 in total

Review 1.  Promising new treatment targets in patients with fibrosing lung disorders.

Authors:  Martina Sterclova; Martina Vasakova
Journal:  World J Clin Cases       Date:  2014-11-16       Impact factor: 1.337

2.  Interstitial Pneumonia with Autoimmune Features: Overview of proposed criteria and recent cohort characterization.

Authors:  Cathryn T Lee; Justin M Oldham
Journal:  Clin Pulm Med       Date:  2017-09

Review 3.  Interstitial Pneumonia with Autoimmune Features.

Authors:  Bridget A Graney; Aryeh Fischer
Journal:  Ann Am Thorac Soc       Date:  2019-05

4.  Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement.

Authors:  Andreina Manfredi; Marco Sebastiani; Stefania Cerri; Giulia Cassone; Pietrantonio Bellini; Giovanni Della Casa; Fabrizio Luppi; Clodoveo Ferri
Journal:  Clin Rheumatol       Date:  2017-03-21       Impact factor: 2.980

5.  Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year.

Authors:  Bridget F Collins; Charles F Spiekerman; Megan A Shaw; Lawrence A Ho; Jennifer Hayes; Carolyn A Spada; Caroline M Stamato; Ganesh Raghu
Journal:  Chest       Date:  2017-03-12       Impact factor: 9.410

Review 6.  Interstitial lung disease in connective tissue disease--mechanisms and management.

Authors:  Athol U Wells; Christopher P Denton
Journal:  Nat Rev Rheumatol       Date:  2014-09-30       Impact factor: 20.543

7.  A retrospective study of prognostic factors in patients with interstitial pneumonia receiving long-term oxygen therapy.

Authors:  Masayoshi Higashiguchi; Takashi Kijima; Hiromitsu Sumikawa; Osamu Honda; Toshiyuki Minami; Haruhiko Hirata; Koji Inoue; Izumi Nagatomo; Yoshito Takeda; Hiroshi Kida; Noriyuki Tomiyama; Atsushi Kumanogoh
Journal:  Lung       Date:  2014-07-24       Impact factor: 2.584

8.  National Registry of Interstitial Lung Disease from Pakistan.

Authors:  Ali Bin Sarwar Zubairi; Mosavir Ansarie; Talha Mahmud; Saadia Ashraf; Nisar Ahmed Rao; Arshad Javaid; Zubair Shaheen; Shereen Khan; Afzaalullah Khan
Journal:  Cureus       Date:  2021-04-25

Review 9.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

Review 10.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.